HIKAL240.36

Hikal Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersPANACEABIODCALSAIPARENTINDOCOSOLARAWINDLASINDSWFTLABHESTERBIOMcap ₹2,968 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q2 FY24
30/09/2023
Q3 FY24
31/12/2023
Q4 FY24
31/03/2024
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations434.9447.6514.1406.8452.9447.7552.4380.4318.5494.3519.4402.8
Other Income1.00.10.50.50.43.60.51.01.92.86.61.8
Total Income435.9447.6514.6407.3453.3451.3552.9381.4320.4497.1526.0404.6
Expenses
+ Cost of Materials Consumed212.3192.6183.2234.8224.3212.8210.7182.0218.7187.6210.3194.0
+ Changes in Inventories0.814.251.1-42.5-22.4-1.921.54.8-92.444.46.3-11.4
+ Employee Benefit Expense61.861.363.857.162.164.563.462.969.670.667.274.4
+ Finance Costs13.114.215.319.818.818.717.917.114.915.514.614.9
+ Depreciation & Amortisation28.629.032.331.831.733.237.739.441.241.242.042.7
+ Other Expenses102.4114.7121.699.4114.0100.2133.4105.6115.4109.0130.2108.8
Total Expenses419.0426.0467.2400.4428.5427.5484.6411.8367.4468.3470.6423.4
EBITDA57.564.894.558.074.972.1123.425.17.282.7105.437.0
EBIT29.035.862.126.243.238.985.7-14.3-34.041.563.4-5.7
Profit
PBT before Exceptional Items16.921.647.36.924.823.868.3-30.4-47.028.855.4-18.8
+ Exceptional Items0.00.00.00.00.00.00.00.00.0-38.0-47.18.9
Pretax Income16.921.647.36.924.823.868.3-30.4-47.0-9.28.3-9.9
+ Current Tax4.55.216.01.56.74.517.30.00.00.0-2.00.0
+ Deferred Tax-0.20.3-2.60.3-0.22.10.8-8.0-12.1-3.3-4.1-2.5
Tax Expense4.35.513.41.86.56.618.1-8.0-12.1-3.3-6.1-2.5
Net Income12.616.134.05.118.317.250.2-22.4-34.9-5.914.4-7.4
+ Net Income — Continuing Ops12.616.134.05.118.317.250.2-22.4-34.9-5.914.4-7.4
+ Other Comprehensive Income-0.1-0.1-0.2-0.1-0.2-0.1-1.0-0.4-0.40.0-1.60.2
Total Comprehensive Income12.416.033.85.018.117.149.2-22.8-35.3-5.912.8-7.2
Per Share
Basic EPS1.021.312.760.411.481.394.07-1.82-2.83-0.481.17-0.60
Diluted EPS1.021.312.760.411.481.394.07-1.82-2.83-0.481.17-0.60
Other Comprehensive Income — detail
+ Other Comprehensive Income-1.0-0.4-0.40.0-1.60.2
+ Items NOT to be Reclassified to P&L-0.2-0.2-0.30.0-0.2-0.50.0
+ Tax on Items NOT to be Reclassified1.2-0.10.50.02.2-0.2
+ Tax on Items NOT to be Reclassified — alt tag-0.1-0.0-0.10.20.3-0.1
+ Tax on Items to be Reclassified-0.20.0-0.10.0-0.60.0
+ Tax on Items to be Reclassified — alt tag0.00.00.0-0.1-0.1
Per Share — as-filed variants
Basic EPS — Continuing Operations1.021.312.760.411.481.394.07-1.820.00-0.481.17-0.60
Diluted EPS — Continuing Operations1.021.312.760.411.481.394.07-1.820.00-0.481.17-0.60
Basic EPS — Discontinued Operations0.000.000.000.000.000.000.000.00-2.830.000.000.00
Diluted EPS — Discontinued Operations0.000.000.000.000.000.000.000.00-2.830.000.000.00
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit221.8240.8279.9214.5251.0236.8320.2193.6192.2262.3302.8220.2
Gross Margin %50.9953.7954.4352.7355.4252.8957.9750.8960.3553.0658.3054.67
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)16.921.647.36.924.823.868.3-30.4-47.028.855.4-18.8
− Exceptional Items (reconciliation)0.00.00.00.00.00.00.00.00.0-38.0-47.18.9
Net Income Adj (tax-effected)12.616.134.05.118.317.250.2-22.4-34.918.561.5-14.1
EPS Adj1.021.312.760.411.481.394.07-1.82-2.831.505.00-1.14
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value2.002.002.002.002.002.002.002.002.002.002.002.00
Filed Debt Equity0.000.010.010.010.010.010.01
Filed Dscr0.000.010.010.010.010.010.01
Filed Iscr0.000.040.080.030.030.040.04
Paid Up Equity Capital24.724.724.724.724.724.724.724.724.724.724.724.7
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.